Safety and efficacy of a novel AAV vector for treatment of hemophilia B

被引：0
|
作者：
Anguela, X. [1 ,2 ]
Toso, R. [2 ]
Couto, L. B. [2 ]
Chen, Y. [2 ]
Hui, D. [2 ]
DiPietro, M. [2 ]
Lee, B. [1 ]
Qu, G. [2 ]
Hauck, B. [2 ]
Corbau, R. [1 ,2 ]
Wright, F. [2 ]
High, K. A. [2 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Spark Therapeut Inc, Philadelphia, PA USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO172-MON
引用
收藏
页码：324 / 325
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
    George, Lindsey A.
    Sullivan, Spencer K.
    Rasko, John E. J.
    Giermasz, Adam
    Samelson-Jones, Benjamin J.
    Ducore, Jonathan M.
    Teitel, Jerome M.
    McGuinn, Catherine E.
    Runowski, Alexa R.
    Wright, Fraser
    Anguela, Xavier M.
    High, Katherine A.
    Rybin, Denis
    Murphy, John E.
    Rupon, Jeremy
    BLOOD, 2019, 134
  • [2] Evaluation of AAV Vectors for the Treatment of Hemophilia A and B
    Alan McClelland
    Nature Biotechnology, 1999, 17 (Suppl 4) : 22 - 22
  • [3] Development of recombinant AAV-FVIII vector for prophylactic treatment of hemophilia A
    Stepan, T
    Monsun, K
    Sandalon, Z
    Lippa, M
    Rogers, L
    Lynch, C
    Burstein, H
    MOLECULAR THERAPY, 2003, 7 (05) : S191 - S191
  • [4] Gene therapy for hemophilia B by novel serotypes of AAV vectors
    Wang, LL
    Gao, GP
    Bell, P
    Sanmiguel, J
    Li, Y
    Nichols, TC
    Verma, IM
    Wilson, JM
    MOLECULAR THERAPY, 2003, 7 (05) : S26 - S26
  • [5] Novel pseudotyped AAV vectors for hemophilia B gene therapy
    Wang, LL
    Louboutin, JP
    Nichols, TC
    Wilson, JM
    MOLECULAR THERAPY, 2004, 9 : S61 - S62
  • [6] Development of an AAV Gene Therapy Vector FT-004 for Hemophilia B
    Shi, Zhong-Dong
    Patkar, Chinmay
    Fang, Yiling
    Ren, Chao
    MOLECULAR THERAPY, 2024, 32 (04) : 518 - 519
  • [7] Development of recombinant AAV-FVIII vector for prophylactic treatment of Hemophilia A.
    Stepan, TM
    Munson, KL
    Sandalon, Z
    DeHass, D
    Lippa, MS
    Rogers, LC
    Thompson, SA
    Dorner, A
    Lynch, CM
    Burstein, H
    BLOOD, 2002, 100 (11) : 484B - 484B
  • [8] Development of an AAV8-based gene therapy vector for hemophilia A treatment
    Falkner, F. G.
    Horling, F.
    Lengler, J.
    Mayrhofer, J.
    Weiller, M.
    Hoellriegl, W.
    Rottensteiner, H.
    Scheiflinger, F.
    HUMAN GENE THERAPY, 2016, 27 (11) : A154 - A154
  • [9] A novel method of regional intravenous delivery of AAV vector to skeletal muscle results in correction of canine hemophilia B phenotype
    Arruda, VR
    Stedman, HH
    Schuettrumpf, J
    Jiang, HY
    Pierce, G
    Nichols, TC
    High, KA
    BLOOD, 2004, 104 (11) : 868A - 869A
  • [10] Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B
    Barbara Dietrich
    Alexandra Schiviz
    Werner Hoellriegl
    Frank Horling
    Karima Benamara
    Hanspeter Rottensteiner
    Peter L. Turecek
    Hans Peter Schwarz
    Friedrich Scheiflinger
    Eva-Maria Muchitsch
    International Journal of Hematology, 2013, 98 : 525 - 532
12345